Inhibrx (NASDAQ:INBX) Earns Market Perform Rating from JMP Securities

Inhibrx (NASDAQ:INBX)‘s stock had its “market perform” rating reaffirmed by research analysts at JMP Securities in a research report issued to clients and investors on Wednesday,Benzinga reports.

Inhibrx Stock Performance

INBX opened at $13.09 on Wednesday. The company’s 50 day moving average is $14.64 and its 200-day moving average is $14.66. Inhibrx has a 1-year low of $10.80 and a 1-year high of $18.95.

Insider Activity

In other Inhibrx news, Director Jon Faiz Kayyem acquired 69,686 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average price of $14.23 per share, for a total transaction of $991,631.78. Following the acquisition, the director now directly owns 51,093 shares in the company, valued at $727,053.39. This represents a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 22.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inhibrx stock. Exchange Traded Concepts LLC acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,608 shares of the company’s stock, valued at approximately $148,000. Exchange Traded Concepts LLC owned about 0.07% of Inhibrx at the end of the most recent reporting period. 82.46% of the stock is owned by institutional investors and hedge funds.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.